IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +50.00% and +6.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?